An Update Of Improvemf: Dose-escalation Of Imetelstat + Ruxolitinib In Patients With Myelofibrosis

2025 2:46
Synopsis
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, discusses early results from the IMproveMF trial (NCT05371964), ...

You Might Also Like

IMPROVE-MF: imetelstat and ruxolitinib in patients with myelofibrosis 1:30
Improve-mf: Imetelstat And Ruxolitinib In Patients With Myel...
2024
The IMproveMF study: combining imetelstat with ruxolitinib for the treatment of myelofibrosis 0:58
The Improvemf Study: Combining Imetelstat With Ruxolitinib F...
2025
An update on imetelstat in R/R myelofibrosis 1:44
An Update On Imetelstat In R/r Myelofibrosis
2022
Phase I dose-escalation study of the BET inhibitor INCB057643 in R/R myelofibrosis 1:52
Phase I Dose-escalation Study Of The Bet Inhibitor Incb05764...
2023
Imetelstat shows promise in advanced myelofibrosis 4:39
Imetelstat Shows Promise In Advanced Myelofibrosis
2020
Ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis 1:15
Ongoing Trials Of Ruxolitinib, Momelotinib And Imetelstat In...
2017
Updates from the RESTORE trial of elritercept plus ruxolitinib in patients with MF and anemia 1:38
Updates From The Restore Trial Of Elritercept Plus Ruxolitin...
2025
An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia 2:21
An Update From Limber-104: Zilurgisertib +/- Ruxolitinib In ...
2024
Phase II study update of navtemadlin in patients with myelofibrosis R/R to ruxolitinib 3:44
Phase Ii Study Update Of Navtemadlin In Patients With Myelof...
2023
Adam Mead, MD, on PROMise trial updates in myelofibrosis 4:35
Adam Mead, Md, On Promise Trial Updates In Myelofibrosis
2025
Therapies for patients who progress on JAK inhibitors: imetelstat, navtemadlin, selinexor & TP-3654 3:13
Therapies For Patients Who Progress On Jak Inhibitors: Imete...
2023
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.